Recent News for ALKS - Alkermes plc

Date Title
Apr 8 Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
Apr 7 Alkermes and Merck team up for late-stage ovarian cancer study
Apr 7 Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer
Mar 31 An Intrinsic Calculation For Alkermes plc (NASDAQ:ALKS) Suggests It's 30% Undervalued
Mar 25 Alkermes to Take Part in Stifel's 3rd Annual CNS Day
Mar 25 Alkermes to target 30% non-GAAP margin by 2024
Mar 25 Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy
Mar 21 Alkermes may see further pressure from activist Sarissa Capital
Mar 19 Seeking Alpha Catalyst Watch
Mar 11 Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Mar 10 Alkermes gets FDA orphan tag in mucosal melanoma
Mar 8 Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' term loan; stable outlook
Mar 4 Alkermes to Hold Virtual Investor Day
Feb 18 Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference
Feb 12 Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
Feb 12 The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed
Feb 11 Alkermes PLC (ALKS) Q4 2020 Earnings Call Transcript
Feb 11 Alkermes plc (ALKS) CEO Richard Pops on Q4 2020 Results - Earnings Call Transcript
Feb 11 Alkermes plc 2020 Q4 - Results - Earnings Call Presentation
Feb 11 Why Alkermes' Q4 Results Were Better Than They Might Seem
Feb 11 Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates
Feb 11 Alkermes Q4 topline slumps, provides 2021 forecast
Feb 11 The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Feb 11 Alkermes EPS beats by $0.03, beats on revenue
Feb 11 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
Back to the Main ALKS Page...